Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amélie Darlix

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Bulletin Du Cancer|December 31, 2021
Thomas Bachelot, Caroline Bailleux, Amélie Darlix, et al.
Neuro-Chirurgie|December 22, 2024
Epidemiological analysis of adult-type diffuse lower-grade gliomas and incidence and prevalence estimates of diffuse IDH-mutant gliomas in FranceLuc Bauchet, Valérie Rigau, Bertrand Mathon, et al.
Frontiers in Oncology|November 19, 2019
High Levels of Cartilage Oligomeric Matrix Protein in the Serum of Breast Cancer Patients Can Serve as an Independent Prognostic MarkerKonstantinos S Papadakos, Amélie Darlix, William Jacot, et al.
Neurology|January 24, 2020
Postoperative follow-up for selected diffuse low-grade gliomas with WHO grade III/IV fociAmélie Darlix, Valérie Rigau, Julien Fraisse, et al.
Critical Reviews in Oncology/Hematology|December 25, 2016
The etiopathogenesis of diffuse low-grade gliomasAmélie Darlix, Catherine Gozé, Valérie Rigau, et al.
International Journal of Cancer|July 1, 2021
Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancerAmélie Darlix, Christophe Hirtz, Caroline Mollevi, et al.
The Lancet Regional Health. Europe|October 9, 2024
Long-term autonomy, professional activities, cognition, and overall survival after awake functional-based surgery in patients with IDH-mutant grade 2 gliomas: a retrospective cohort studySam Ng, Valérie Rigau, Sylvie Moritz-Gasser, et al.
Neuro-Oncology Practice|January 8, 2025
Who will benefit from vorasidenib? Review of data from the literature and open questionsAmélie Darlix, Matthias Preusser, Shawn L Hervey-Jumper, et al.
Frontiers in Oncology|August 3, 2023
Bevacizumab in recurrent WHO grades II-III gliomaSoufyan Annakib, Valérie Rigau, Amélie Darlix, et al.
Frontiers in Psychology|October 9, 2025
Efficacy of hybrid remote neuropsychological rehabilitation on cognitive complaints in post-therapeutic lower-grade glioma: the FREEDOME randomized study protocolEstelle Guerdoux, Louise Coutant, Sophie Gourgou, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Bulletin Du Cancer|December 31, 2021
Thomas Bachelot, Caroline Bailleux, Amélie Darlix, et al.
Neuro-Chirurgie|December 22, 2024
Epidemiological analysis of adult-type diffuse lower-grade gliomas and incidence and prevalence estimates of diffuse IDH-mutant gliomas in FranceLuc Bauchet, Valérie Rigau, Bertrand Mathon, et al.
Frontiers in Oncology|November 19, 2019
High Levels of Cartilage Oligomeric Matrix Protein in the Serum of Breast Cancer Patients Can Serve as an Independent Prognostic MarkerKonstantinos S Papadakos, Amélie Darlix, William Jacot, et al.
Neurology|January 24, 2020
Postoperative follow-up for selected diffuse low-grade gliomas with WHO grade III/IV fociAmélie Darlix, Valérie Rigau, Julien Fraisse, et al.
Critical Reviews in Oncology/Hematology|December 25, 2016
The etiopathogenesis of diffuse low-grade gliomasAmélie Darlix, Catherine Gozé, Valérie Rigau, et al.
International Journal of Cancer|July 1, 2021
Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancerAmélie Darlix, Christophe Hirtz, Caroline Mollevi, et al.
The Lancet Regional Health. Europe|October 9, 2024
Long-term autonomy, professional activities, cognition, and overall survival after awake functional-based surgery in patients with IDH-mutant grade 2 gliomas: a retrospective cohort studySam Ng, Valérie Rigau, Sylvie Moritz-Gasser, et al.
Neuro-Oncology Practice|January 8, 2025
Who will benefit from vorasidenib? Review of data from the literature and open questionsAmélie Darlix, Matthias Preusser, Shawn L Hervey-Jumper, et al.
Frontiers in Oncology|August 3, 2023
Bevacizumab in recurrent WHO grades II-III gliomaSoufyan Annakib, Valérie Rigau, Amélie Darlix, et al.
Frontiers in Psychology|October 9, 2025
Efficacy of hybrid remote neuropsychological rehabilitation on cognitive complaints in post-therapeutic lower-grade glioma: the FREEDOME randomized study protocolEstelle Guerdoux, Louise Coutant, Sophie Gourgou, et al.
Pageof 6